Consensus $8.75. Raises FY24 revenue view to $9.4B-$9.48B from $9.35B-$9.45B, consensus $9.4B. Backs FY24 capital expenditures view $420M. “In addition, our Invigorate initiative, which includes ongoing investments in automation and AI, continued to improve productivity as well as service levels and quality. Given the strength of our business, we are raising our revenue and adjusted earnings guidance for the full year,” Davis said.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $138 from $135 at Baird
- Quest Diagnostics and Broad Clinical Labs announce collaboration
- Ex-Dividend Date Nearing for These 10 Stocks – Week of April 1, 2024
- Quest Diagnostics management to meet with UBS
- Moderna downgraded, Gap upgraded: Wall Street’s top analyst calls
